One cupcake won't kill you,' 'I'm going to get diabetes just looking at that,' 'That person doesn't look like they have ...

Abbott (NYSE:ABT) today unveiled a new initiative addressing the biases and stigmas associated with diabetes management.

When you buy through our links, we may earn a commission. Learn more› By Dave Gershgorn Dave Gershgorn is a writer covering monitors, laptops, and tablets. He is a certified display calibrator ...

Medical device and healthcare company Abbott has opened a new facility in Kilkenny, which is expected to employ 800 people.

Investors feel optimistic about Abbott's robust strength in the Core Diagnostics business. Yet, unfavorable forex impacts are concerning.

Abbott's Diabetes Care business continues to benefit from the growing sales of its flagship, sensor-based continuous glucose ...

Financial analysis of Abbott Laboratories Q4 2024 results and 2025 outlook, with a 'Buy' rating due to revenue growth and EPS ...

Abbott Laboratories is a well-diversified health care company, with four distinct units: medical devices, diagnostics, ...

A few weeks ago, an allergist prescribed a two-week course of an oral steroid to clear up my sinus inflammation. Before I ...

Abbott Laboratories on Wednesday forecast first-quarter profit below Wall Street as weakness in nutrition and diagnostics units overshadowed strength in medical devices, sending its shares down more ...

CEO Robert Ford also plans to expand sales of the company’s Lingo over-the-counter glucose sensors after a limited rollout.

Abbott (NYSE:ABT) today highlighted significant growth within its Diabetes business amid its fourth-quarter results for 2024.